Evidence map›Paper›PMID 41376941›Full record

ArticleJournal of thoracic disease2025

SCM-198 ameliorates pulmonary arterial hypertension by modulating gut microbiota in rats.

Jianyu Xiong, Qinyang Ge, Bohan Fu, Jiayao Li, Zhongxiao Lin, Yi Zhun Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jianyu XiongLaboratory of Drug Discovery from Natural Resources and Industrialization and Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
Qinyang GeLaboratory of Drug Discovery from Natural Resources and Industrialization and Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
Bohan FuLaboratory of Drug Discovery from Natural Resources and Industrialization and Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
Jiayao LiLaboratory of Drug Discovery from Natural Resources and Industrialization and Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
Zhongxiao LinLaboratory of Drug Discovery from Natural Resources and Industrialization and Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
Yi Zhun ZhuLaboratory of Drug Discovery from Natural Resources and Industrialization and Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary disorder characterized by pulmonary vascular remodeling and inflammation. This study aimed to investigate the therapeutic effects of SCM-198 ( Methods: A rat model of PAH was established via one-time intraperitoneal injection of MCT (50 mg/kg), followed by SCM-198 treatment (50 and 100 mg/kg) for 3 weeks. Pulmonary vascular remodeling was assessed by histological and morphometric analyses. 16S rRNA sequencing was performed to evaluate gut microbiota diversity and composition. Network pharmacology analysis was conducted to identify SCM-198 targets, including overlapping targets related to PAH, and to explore relevant signaling pathways via protein-protein interaction (PPI) networks, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Results: SCM-198 treatment significantly attenuated pulmonary arterial wall thickening and vascular remodeling. Microbial diversity exhibited a trend toward restoration, with increased abundance of Conclusions: These findings suggest that SCM-198 exerts therapeutic effects in PAH through combined gut microbiota modulation and multi-target regulation of vascular signaling networks, offering new insights into adjunctive strategies for PAH treatment.

Indexed as

gut floraleonurine (SCM-198)network pharmacologyPulmonary arterial hypertension (PAH)

Identifiers

PMID41376941
PMCPMC12688580

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.